María José Terol
机构：Universitat de València, Hospital Clínico Universitario de Valencia, Biomedical Research Institute, INCLIVA Health Research Institute · ORCID：0000-0002-9467-932X
发表论文 277 篇 · 总被引 6930 次 · h-index 39
代表论文
- Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study (2024 · Blood · 被引 14)
- Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial (2025 · Journal of Clinical Oncology · 被引 13)
- ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker (2025 · Leukemia · 被引 5)
- Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model (2024 · EJNMMI Research · 被引 5)
- Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR‐T Therapy (2025 · eJHaem · 被引 4)
- Guía para el diagnóstico y el tratamiento de la leucemia linfocítica crónica y el linfoma linfocítico de células pequeñas del Grupo Español de Leucemia Linfocítica Crónica (GELLC) (2025 · Medicina Clínica · 被引 4)